R. E. Millikan
Impact in
-
- Carcinogens and Genotoxicity Assessment
-
- Drug Transport and Resistance Mechanisms
Papers in
-
- Prostate Cancer Treatment and Research 5
- Renal cell carcinoma treatment 3
- Prostate Cancer Diagnosis and Treatment 2
-
- Protein Degradation and Inhibitors 2
- Renal and related cancers 2
- Co-authors
- Jian Gu (2 shared papers)H. Barton Grossman (2 shared papers)Colin P. Dinney (2 shared papers)Xifeng Wu (2 shared papers)Carol J. Etzel (1 shared paper)Margaret R. Spitz (1 shared paper)Qing Zhang (1 shared paper)Maosheng Huang (1 shared paper)
- Journals
- Journal of Clinical Oncology (6 papers)JNCI Journal of the National Cancer Institute (2 papers)Annals of Oncology (1 paper)Gastroenterology (1 paper)The American Journal of Human Genetics (1 paper)
- Partner nations
- United StatesSpain
In The Last Decade
R. E. Millikan
13 papers receiving 603 citations
Peers
Comparison fields: 5 of 73
- Cancer Research 88
- Oncology 129
- Statistics and Probability 31
- Surgery 141
- Molecular Biology 240
Countries citing papers authored by R. E. Millikan
This map shows the geographic impact of R. E. Millikan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. E. Millikan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. E. Millikan more than expected).
Fields of papers citing papers by R. E. Millikan
This network shows the impact of papers produced by R. E. Millikan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. E. Millikan. The network helps show where R. E. Millikan may publish in the future.
Co-authors
The 25 scholars most cited alongside R. E. Millikan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2006 | 234 | |
| 2 | 2005 | 137 | |
| 3 | 2001 | 68 | |
| 4 | Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. | 1997 | 67 |
| 5 | 2007 | 50 | |
| 6 | 2009 | 28 | |
| 7 | Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. | 1998 | 19 |
| 8 | 2011 | 3 | |
| 9 | 2008 | 1 | |
| 10 | 2004 | 1 | |
| 11 | 2004 | 1 | |
| 12 | 2004 | 1 | |
| 13 | 2004 | 1 |
About R. E. Millikan
R. E. Millikan is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Statistics and Probability and Cancer Research, having authored 13 papers that have together received 611 indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (5 papers), Renal cell carcinoma treatment (3 papers), Protein Degradation and Inhibitors (2 papers), Statistical Methods in Clinical Trials (2 papers), Cancer Treatment and Pharmacology (2 papers), Renal and related cancers (2 papers), Prostate Cancer Diagnosis and Treatment (2 papers) and Bladder and Urothelial Cancer Treatments (1 paper). The work is most often cited by research in Cancer Research (88 citations), Oncology (129 citations), Statistics and Probability (31 citations), Surgery (141 citations) and Molecular Biology (240 citations). R. E. Millikan has collaborated with scholars based in United States and Spain. Frequent co-authors include Jian Gu, H. Barton Grossman, Colin P. Dinney, Xifeng Wu, Carol J. Etzel, Margaret R. Spitz, Qing Zhang, Maosheng Huang, Christopher I. Amos and Christopher J. Logothetis. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute, Annals of Oncology, Gastroenterology and The American Journal of Human Genetics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.